Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Dec 15;2(1):46.
doi: 10.1186/1475-2875-2-46.

Molecular monitoring of the Leu-164 mutation of dihydrofolate reductase in a highly sulfadoxine/pyrimethamine-resistant area in Africa

Edwin Ochong  1 , Alexis Nzila, Serah Kimani, Gilbert Kokwaro, Theonest Mutabingwa, William Watkins, Kevin Marsh
Affiliations

Molecular monitoring of the Leu-164 mutation of dihydrofolate reductase in a highly sulfadoxine/pyrimethamine-resistant area in Africa

Edwin Ochong et al. Malar J. .

Abstract

The selection of point mutation at codon 164 (from isoleucine to leucine) of the dihydrofolate reductase (DHFR) enzyme in Plasmodium falciparum is associated with high sulfadoxine /pyrimethamine (SP) resistance. Using the yeast expression system that allows the detection of dhfr allele present at low level, the presence of this mutation had previously been reported between 1998-1999 in Muheza, Tanzania, an area of high SP resistance. Eighty five P. falciparum isolates, obtained from the same area between 2002 and 2003, were analysed for the presence of Leu-164 mutation, using standard protocol based on PCR-RFLP. None of the isolates had the Leu-164 mutation.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Mutabingwa T, Nzila A, Mberu E, Nduati E, Winstanley P, Hills E, Watkins W. Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet. 2001;358:1218–23. doi: 10.1016/S0140-6736(01)06344-9. - DOI - PubMed
    1. Winstanley P. Chlorproguanil-dapsone (LAPDAP) for uncomplicated falciparum malaria. Trop Med Int Health. 2001;6:952–954. doi: 10.1046/j.1365-3156.2001.00751.x. - DOI - PubMed
    1. Lang T, Greenwood B. The development of Lapdap, an affordable new treatment for malaria. Lancet Infect Dis. 2003;3:162–168. doi: 10.1016/S1473-3099(03)00547-4. - DOI - PubMed
    1. Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, Mberu EK, Cowman AF, Winstanley PA, Watkins WM, Nzila AM. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol. 2001;17:582–528. doi: 10.1016/S1471-4922(01)02085-2. - DOI - PubMed
    1. Watkins WM, Mberu EK, Winstanley PA, Plowe CV. The Efficacy of antifolate antimalarial combination in africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol Today. 1997;13:459–464. doi: 10.1016/S0169-4758(97)01124-1. - DOI - PubMed

LinkOut - more resources